目的 觀察疏血通注射液聯(lián)合腎康注射液治療急性腎損傷的臨床療效。方法 選取2013年1月-2015年1月徐州醫(yī)學(xué)院附屬淮安醫(yī)院收治的急性腎損傷患者112例,隨機分為對照組和治療組,每組各56例。對照組在基礎(chǔ)治療上靜脈滴注腎康注射液,100 mL/次加入5%葡萄糖注射液300 mL中,1次/d。治療組在對照組的基礎(chǔ)上靜脈滴注疏血通注射液,6 mL/次加入5%葡萄糖注射液250 mL,1次/d。兩組均連續(xù)治療21 d。觀察兩組的臨床療效,同時比較血肌酐(Scr)、內(nèi)生肌酐清除率(CCR)、尿β₂-微球蛋白(β₂-MG)、尿滲透壓、尿素氮(BUN)、24 h尿蛋白(Upro)、血清芳香酯酶(ArE)、總膽固醇(TC)、高密度脂蛋白膽固醇(HDL-C)、載脂蛋白A(Apo-A)、載脂蛋白B(Apo-B)、急性生理學(xué)與慢性健康狀況(A-PACHEⅡ)評分的變化。結(jié)果 治療后,對照組和治療組的總有效率分別為71.43%、87.50%,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05)。治療7、14、21 d兩組Scr均呈下降趨勢,CCR呈上升趨勢,同組治療前后差異具有統(tǒng)計學(xué)意義(P < 0.05);且治療組Scr、CCR的改善程度優(yōu)于同期對照組水平,兩組比較差異具有統(tǒng)計學(xué)意義(P < 0.05)。治療后,兩組患者β₂-MG、Scr、BUN、Upro、TC、Apo-B、A-PACHEⅡ評分均顯著降低,尿滲透壓、ArE、HDL-C、Apo-A均顯著升高,同組治療前后差異具有統(tǒng)計學(xué)意義(P < 0.05);且治療組這些觀察指標(biāo)的改善程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P < 0.05)。結(jié)論 疏血通注射液聯(lián)合腎康注射液治療急性腎損傷療效確切,可顯著改善患者腎功能及血脂指標(biāo),具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical efficacy of Shuxuetong Injection combined with Shenkang Injection in treatment of acute kidney injury. Methods Patients (112 cases) with acute kidney injury in Huai'an Hospital Affiliated to Xuzhou Medical College from January 2013 to January 2015 were randomly divided into control and treatment groups, and each group had 56 cases. The patients in control group were iv administered with Shenkang Injection, 100 mL/time Shenkang Injection added into 5% glucose injection 300 mL, once daily. The patients in treatment group were iv administered with Shuxuetong Injection on the basis of control group, 6 mL/time Shenkang Injection added into 5% glucose injection 250 mL, once daily. Two groups were treated for 21 d. After treatment, the efficacy was evaluated, and the changes of Scr, CCR, β₂-MG, urine osmotic pressure, BUN, Upro, ArE, TC, HDL-C, Apo-A, Apo-B, A-PACHEⅡ scores in two groups before and after treatment were compared. Results After treatment, the efficacies in control and treatment groups were 71.43% and 87.50%, respectively, and there were differences between two groups (P < 0.05). After treatment of 7, 14, and 21 d, Scr levels in two groups presented a downward trend, CCR presented a rising trend, and the difference was statistically significant in the same group (P < 0.05). After treatment, β₂-MG, Scr, BUN, Upro, TC, Apo-B, and A-PACHEⅡ scores in two groups were significantly decreased, and urine osmotic pressure, ArE, HDL-C, and Apo-A were increased, and the difference was statistically significant in the same group (P < 0.05). The improvement degrees of observational indexes were better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Shuxuetong Injection combined with Shenkang Injection has curative effect in treatment of acute kidney injury, and can significantly improve the kidney function and blood lipids index, which has a certain clinical application value.